- Home
- AVIR vs GALT Comparison
AVIR vs GALT Comparison
Compare AVIR & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AVIR | GALT |
|---|---|---|
| Founded | 2012 | 2000 |
| Country | United States | United States |
| Employees | 55 | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 334.5M | 397.3M |
| IPO Year | 2020 | 2008 |
Fundamental Metrics
Financial Performance| Metric | AVIR | GALT |
|---|---|---|
| Price | $4.43 | $3.48 |
| Analyst Decision | Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $8.50 | N/A |
| AVG Volume (30 Days) | ★ 283.2K | 182.8K |
| Earning Date | 11-09-2026 | 11-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 3.00 | ★ 36.84 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $351,367,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.87 | $2.03 |
| 52 Week High | $6.45 | $7.13 |
Technical Indicators
Market Signals| Indicator | AVIR | GALT |
|---|---|---|
| Relative Strength Index (RSI) | 35.94 | 41.77 |
| Support Level | $4.06 | $2.71 |
| Resistance Level | $4.69 | $4.10 |
| Average True Range (ATR) | 0.26 | 0.23 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 27.43 | 32.88 |
Price Performance
Historical ComparisonAbout AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.